SCHEMBL23734388

SCHEMBL23734388

COCSSCOC1C[C@H](n2cc(C)c(=O)[nH]c2=O)O[C@@H]1CO

nearest known ligand 0.66

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
RNASE1 P07998 1/20 0.61
TK1 P04183 7/20 0.60
LMNA P02545 2/20 0.56
TSHR P16473 2/20 0.56
ALB P02768 1/20 0.56
PKM P14618 1/20 0.56
BLM P54132 1/20 0.56
PMP22 Q01453 1/20 0.56
CYP2D6 P10635 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6224637 0.89 TK1 (0.67) RNASE1TK1LMNATSHRALB
SCHEMBL28338723 0.89 TK1 (0.67) RNASE1TK1LMNATSHRALB
SCHEMBL24913674 0.89 RNASE1 (0.64) RNASE1TK1LMNATSHRALB
SCHEMBL19662165 0.88 TK1 (0.61) RNASE1TK1LMNATSHRALB
SCHEMBL22074477 0.87 RNASE1 (0.66) RNASE1TK1LMNATSHRALB
SCHEMBL26571124 0.87 RNASE1 (0.68) RNASE1TK1LMNATSHRALB
SCHEMBL6248265 0.87 RNASE1 (0.68) RNASE1TK1LMNATSHRALB
SCHEMBL16360133 0.87 RNASE1 (0.68) RNASE1TK1LMNATSHRALB
SCHEMBL29834203 0.86 RNASE1 (0.64) RNASE1TK1LMNATSHRALB
SCHEMBL523267 0.86 RNASE1 (0.69) RNASE1TK1LMNATSHRALB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230160000-A1 SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-05-25 US disclosed
US-20230160000-A1 SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-05-25 US disclosed
US-20230028388-A1 DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-01-26 US disclosed
US-20220411860-A1 DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2022-12-29 US disclosed
US-11085076-B2 Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2021-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411860-A1 DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS POLL, POLQ, POLB RNASE1 872/4885TK1 54/4885LMNA 337/4885
US-20230028388-A1 DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS RNGTT, POLRMT, MTR RNASE1 1166/4885TK1 107/4885LMNA 1084/4885
US-11085076-B2 Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis POLRMT, RNGTT, MTR RNASE1 1358/4885TK1 78/4885LMNA 984/4885
US-20230160000-A1 SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS POLRMT, RNGTT, MTR RNASE1 1358/4885TK1 78/4885LMNA 984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.